What question did this study set out to answer?

This trial aims to evaluate the efficacy and safety of KAT6 inhibitor PF-07248144 combined with fulvestrant in HR+HER2− advanced breast cancer after progression on CDK4/6 inhibitors.

February 19, 2026Clinical Cancer Research

Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

View Full Paper

Ask AI

Bookmark

Authors

KKK. M. KalinskyEmory University RLR. M. LaymanThe University of Texas MD Anderson Cancer Center AGA. GiordanoDana-Farber Cancer Institute

Discussion

Member takes

Implication

Randomized trial evaluates efficacy of PF-07248144 plus fulvestrant in advanced breast cancer, indicating a potential treatment advancement.

Key Points

This trial aims to evaluate the efficacy and safety of KAT6 inhibitor PF-07248144 combined with fulvestrant in HR+HER2− advanced breast cancer after progression on CDK4/6 inhibitors.
Open-label, randomized phase 3 trial design
Comparing PF-07248144 plus fulvestrant to everolimus plus endocrine therapy
Involving up to 400 patients with HR+HER2− advanced breast cancer
Key inclusion criteria included age ≥ 18, confirmed ABC, and measurable disease
Primary endpoint is progression-free survival as assessed by independent review.
Encouraging initial findings from phase 1/2 study suggest durable antitumor activity of PF-07248144 plus fulvestrant.
Primary endpoint of progression-free survival will be compared to standard care.
Overall survival is a key secondary endpoint along with objective response rates and safety evaluations.

Cite This Study

Kalinsky et al. (2026) studied this question.

synapsesocial.com/papers/6996a898ecb39a600b3ef879 https://doi.org/10.1158/1557-3265.sabcs25-ps5-08-19

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates efficacy of PF-07248144 plus fulvestrant in advanced breast cancer, indicating a potential treatment advancement.

Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS5-08-19: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+HER2− advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider